MANAGEMENT OF HASĀH WA RAML AL-KULYA (NEPHROLITHIASIS) IN UNANI SYSTEM OF MEDICINE: A REVIEW
Rashid Ali khan (Department of Amraz-e-Jild wa Zohrawiya wa Tazeeniyat, University College of Unani)
Mohammad Zakir (National Research Institute of Unani Medicine for Skin Disorders (NRIUMSD))
- 다운로드 수
- 조회수
Abstract
The kidneys are exposed to toxicants and waste product and can be affected easily by these toxicants and by products of the metabolism. The consumption of adequate water is necessary to remove waste and to keep kidney healthy. Deficiency of liquid in the blood leads to various adverse effects on the kidney. The most common adverse deficiency of liquid in blood is deposition of solid matter in the kidney and subsequently formation of kidney stone. Nephrolithiasis (kidney stone) can be treated by drugs if it is small in size but if it blocks the route due to its big size then surgery is the only way to remove it. The recurrence rate of the problem is very high and it may reappear within 10 years. In Unani literature Hasāh wa Raml al-Kulya (nephrolithiasis) is described in detail. As per Unani literature stagnation of Ghalīz mādda (filthy and viscous matter) in the kidney is the main cause of the formation of kidney stone. Various single and compound formulations drugs are described for the management of kidney stone which are very effective as well as safe. Management is divided into two parts i.e. symptomatic treatment to relieve pain and to methods adopted to remove stone from the kidney. Musakkin-i-Waja‘(analgesic) drugs are used for pain while Mufattit-i-Hasāh (lithotriptic) and Mudirr-i-Bawl (Diuretic) drugs are used to remove stone. Majoon Aqrab, Qurs Kaknaj and Dawa-e-Gurda etc. are compound drugs mentioned in literature for removal of kidney stone. Single drugs like Alu Balu, Tukhm Khayar, and Kharkhask etc. are also used for same purpose.
- keywords
- Cystolithiasis, Hasah wa Raml, Jarahat, Nephrolithiasis, Unani
참고문헌
Anonymous. American kidney funds: fighting on all fronts, Maryland (USA). Available at: https://www.kidneyfund.org/kidney-disease/kidney-problems/kidney-stones/ (accessed on 22 April 2020b)
Anonymous. National Formulary of Unani Medicine, Part-I. (2006a). (New Delhi, India: CCRUM, Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2006
Anonymous. National Formulary of Unani Medicine, Part-II, Vol-I. (2007). (New Delhi, India: Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2007.
Anonymous. National Formulary of Unani Medicine, Part-IV, first edition. (2006b). (New Delhi, India: Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2006.
Anonymous. National Formulary of Unani Medicine, Part-VI. (2011). (New Delhi, India: Department of AYUSH, Ministry of Health & Family Welfare, Government of India), 2011.
Anonymous. National Kidney Foundation, New York. Available at: https://www.kidney.org/atoz/content/kidneystones (accessed on 22 April 2020a).
Anonymous. Standard Unani Medical Terminology. (New Delhi, India: Central Council for Research in Unani Medicine, Ministry of AYUSH, Govt. of India), 2012
Arzani MA. Meezan al-Tib, National Council for promotion of Urdu language, New Delhi, 1992.
Arzānī MA. Tibb-e-Akbar Urdu, Faisal Publisher, Jama Masjid, Deoband, 1924.
Cheungpasitporn W, Thongprayoon C, O’Corragain OA, Edmonds PJ, Ungprasert P, Kittanamongkolchai W, et al. The risk of kidney cancer in patients with kidney stones: A systematic review and meta\_analysis. QJM, 2015;108:205-12.
Ghani N. Khazainul Advia.: Idara Kitabul Shifa, New Delhi, India, 2011.
Ibn Sīnā. al-Shaykh al-Ra’īs Abū ‘Alī al-Husayn ibn ‘Abd Allāh (1411AH): Al-Qānūn fi’l Tibb, Idara Kitabul Shifa, New Delhi.
Kabir al-Din, Hakim Muhammad. (1894-1976 AD) Ilmul AdviyaNafisi, (New Delhi, India; Aijaz Publishing House), 2007.
Kabir al-Din, Hakim Muhammad. (1894-1976 AD), Kitabul Advia, Vol-II, Makhzanul Mufradat, Daftraul Masih, Hyderbad, 1955.
Khan Ajmal, Hakim Muhammad (1868-1927 AD) Haziq, 27th edition, Hindustani Dawakhana Delhi, 1987, pp. 275-278.
Lieske JC, Pena de la Vega LS, Slezak JM, Bergstralh EJ, Leibson CL, Ho KL, et al. Renal stone epidemiology in Rochester, Minnesota: An update. Kidney Int, 2006;69:760-4.
Long LO, Park S. Update on nephrolithiasis management. Minerva Urol Nefrol,2007;59:317-25.
López M, Hoppe B. History, epidemiology and regional diversities of urolithiasis. Pediatr Nephrol, 2010; 25:49-59.
Nafis ibn ‘Iwad ibn Jamal al-Din al-Mutatabbib al-Kirmani, (1439 AD), Sharh al-Asbab wa’l ‘Alamat, Vol. III-IV, (urdu translation by Hakim Kabīruddīn), (New Delhi,India;Aijaz Publishing House),pp. 305-309.
Rule AD, Lieske JC, Li X, Melton LJ rd, Krambeck AE, BergstralhEJ. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol, 2014;25:2878-86.
Shah J, Whitfield HN. Urolithiasis through the ages. BJU Int.,2002;89:801-89:8
Sofia NH, Manickavasakam K, Walter TM. Prevalence and Risk Factors of Kidney Stone. Global Journal for Research Analysis,2016;5(3):183-187
- 다운로드 수
- 조회수
- 0KCI 피인용수
- 0WOS 피인용수